Photodynamic therapy for Barrett's esophagus with high-grade dysplasia

Comprehensive Therapy

Volumn 31, Issue 2, 2005, Pages 137-144

  Wolfsen, Herbert C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PREDNISONE; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; COLONOSCOPY; DNA DETERMINATION; DRUG EFFICACY; DYSPHAGIA; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HUMAN; LASER SURGERY; LIGHT EXPOSURE; PHOTODYNAMIC THERAPY; SCREENING; SIGMOIDOSCOPY;

BARRETT ESOPHAGUS; CLINICAL TRIALS; DIHEMATOPORPHYRIN ETHER; ESOPHAGOSCOPY; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 26244457613     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:31:2:137     Document Type: Article

References (71)

1. Urbach DR, Baxter NN. Does it matter what a hospital is "high volume" for? Specificity of hospital volume-outcome associations for surgical procedures: analysis of administrative data. BMJ 2004;328:737-740.
2. Wolfsen HC, Hemminger LL, DeVault KR. Recurrent Barrett's esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterol 2004;4:18.
3. Wolfsen HC, Hemminger LL, Wallace MB, DeVault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 2004;20:1-7.
4. Conio M, Lapertosa G, Blanchi S, Filiberti R. Barrett's esophagus: an update. Crit Rev Oncol Hematol 2003;46:187-206.
5. Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 1950;38:175-182.
6. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-859.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
8. Sampliner RE. Long-term endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 2003;98:1912-1913.
9. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-640.
10. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
11. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastrooesophageal reflux. Gut 2004;53:1070-1074.
12. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-467.
13. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-1677.
14. DeVault KR, Ward EM, Wolfsen HC, et al. Symptoms do not predict the presence of Barrett's esophagus in older patients undergoing colonoscopy. Am J Gastroenterol 2003;98:813.
15. DeVault KR, Ward EM, Wolfsen HC, et al. Barrett's esophagus (BE) is common in older patients undergoing screening colonoscopy regardless of gastroestophagea reflux (GER) symptoms (Abstract). Gastrointest Endosc 2004;59:AB111.
16. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99: 918-922.
17. Ormsby AH, Kilgore SP, Goldblum JR, Richter JE, Rice TW, Gramlich TL. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod Pathol 2000;13:614-620.
18. Wolfsen HC, Hemminger LL, DeVault KR. Barrett's dysplasia and mucosal carcinoma patients referred for photodynamic therapy - do they come from surveillance programs? (Abstract). Gastrointest Endosc 2004;59:AB265.
19. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-186.
20. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-2053.
21. Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 2003;35:1059-1068.
22. Dulai G, Jensen D, Saad M, Mawas I, Yu J, Fontana L. Simultaneous screening for Barrett's and colorectal cancer (Abstract). Gastrointest Endosc 2004;59:AB259.
23. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology 2000;37:99-107.
24. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972-1981.
25. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-1362.
26. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-1676.
27. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-1619.
28. Headrick JR, Nichols FC, 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697-702; discussion 1702-1703.
29. Fang M, Lew E, Klein M, Sebo T, Su Y, Goyal R. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. Am J Gastroenterol 2004;99:1887-1894.
30. Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol 2004;99:1657-1666.
31. Bartels H, Stein HJ, Siewert JR. Risk analysis in esophageal surgery. Recent Results Cancer Res 2000;155:89-96.
32. Ikeguchi M, Maeta M, Kaibara N. Respiratory function after esophagectomy for patients with esophageal cancer. Hepatogastroenterology 2002;49:1284-1286.
33. Wang K. Photodynamic therapy made simple. Clinical Perspectives in Gastroenterology 2001;March/April:90-100.
34. Webber J, Herman M, Kessel D, Fromm D. Current concepts in gastrointestinal photodynamic therapy. Ann Surg 1999;230:12-23.
35. Kubba AK. Role of photodynamic therapy in the management of gastrointestinal cancer. Digestion 1999;60:1-10.
36. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7.
37. Malhi-Chowla N, Wolfsen HC, DeVault KR. Esophageal dysmotility in patients undergoing photodynamic therapy. Mayo Clin Proc 2001;76:987-989.
38. Wolfsen HC, Ng CS. Cutaneous consequences of photodynamic therapy. Cutis 2002;69:140-142.
39. Nijhawan PK, Wolfsen HC, Wang KK, Buttar NS, Lutzke L, Anderson M. Cutaneous photosensitivity after photodynamic therapy: Is it really more common in sunny climates'? [abstract]. Gastroenterology 2000;118:A227.
40. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999;49:S20-S23.
41. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 2002;77:1176-1181.
42. Wang KK, Kim JY. Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:483-489, vii.
43. Wolfsen HC, Hemminger LL. Photodynamic therapy for dysplastic Barrett's esophagus and mucosal adenocarcinoma (Abstract). Gastrointest Endosc 2004;59:AB251.
44. Wang KK, Wong Kee Song LM, Buttar NS, Papenfuss S, Lutzke L. Barrett's esophagus after photodynamic therapy: risk of cancer development during long term follow up [abstract]. Gastroenterology 2004;126(suppl 2):A-50.
45. Ukleja A, Scolapio JS, Wolfsen HC. Endoscopic ultrasonography (EUS) and endoscopic mucosal resection (EMR) for staging and treatment of high-grade dysplasia (HGD) and early adenocarcinoma (EAC) in Barrett's esophagus (BE) [abstract]. Gastrotenterology 1999;116:A-582.
46. Mang TS. Laser and light sources for PDT. Photodiag and Photodyn Ther 2004:43-48.
47. 46a. Ban S, Mino M, Nishioka N, et al. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus. AM J. Surg Pathol 2004;28(11):1466-1473.
48. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000;95:2177-2184.
49. Wolfsen HC. Photodynamic therapy for mucosal esophageal adenocarcinoma and dysplastic Barrett's esophagus. Dig Dis 2002;20:5-17.
50. Hemminger LL, Wolfsen HC. Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey. Gastroenterol Nurs 2002;25:139-141.
51. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 2003;48:1273-1283.
52. Shaheen NJ, Inadoni JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's esophagus? A cost effectiveness analysis. Gut 2004;53(12):1736-1744.
53. Wolfsen HC, Hemminger LL, Raimondo M, Woodward TA. Photodynamic therapy and endoscopie mucosal resection for Barrett's dysplasia and early esophageal adenocarcinoma. South Med J 2004;97:827-830.
54. Pacifico RJ, Wang KK. Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surg Oncol Clin N Am 2002;11:321-336.
55. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002;14: 1085-1091.
56. Rajan E, Gostout CJ, Feitoza AB, et al. Widespread EMR: A new technique for removal of large areas of mucosa. Gastrointest Endosc 2004;60:623-627.
57. Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002;97:2998-3006.
58. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000;51:659-663.
59. Ginsberg GG, Barkun AN, Bosco JJ, et al. The argon plasma coagulator: February 2002. Gastrointest Endosc 2002;55:807-810.
60. Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002;51:776-780.
61. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: a useful and realistic option. Technol Cancer Res Treat 2003;2:65-76.
62. Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Flijou JF. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2004;59:880-889.
63. Slehria S, Wei JT, Hall M, Shaheen NJ, Sharma P. The incidence of esophageal adenocarcinoma in paitents with Barrett's esophagus undergoing endoscopie ablation therapy: a sytematic review of the literature. Gastroenterology 2004;126(suppl 2):A-50.
64. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95: 3383-3387.
65. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-378.
66. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32:379-388.
67. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-1256.
68. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-1639.
69. Overholt BF, Lightdale CJ, Wang KK, Canto M. International multi-center partially binded randomized study of the efficacy of photodynamic therapy (PDT) using portimer sodium (POR) for ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE) and results of 24 month follow up. Gastroenterology 2003: A20 [Supplement 1].
70. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-188.
71. Beejay U, Ribeiro A, Hourigan L, et al. Photodynamic therapy of high grade dysplasia with intramucosal carcinoma in Barrett's esophagus - 30 months follow up [abstract]. Gastrointest Endosc 2001;53:AB144.